Literature DB >> 33413496

Regulation of PD-L1 expression in the tumor microenvironment.

Ming Yi1, Mengke Niu1,2, Linping Xu2, Suxia Luo3, Kongming Wu4,5.   

Abstract

Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.

Entities:  

Keywords:  Cancer immunology; PD-1; PD-L1; Post-transcriptional modification; Transcriptional regulation

Year:  2021        PMID: 33413496      PMCID: PMC7792099          DOI: 10.1186/s13045-020-01027-5

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


  153 in total

1.  Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Authors:  Kristin J Lastwika; Willie Wilson; Qing Kay Li; Jeffrey Norris; Haiying Xu; Sharon R Ghazarian; Hiroshi Kitagawa; Shigeru Kawabata; Janis M Taube; Sheng Yao; Linda N Liu; Joell J Gills; Phillip A Dennis
Journal:  Cancer Res       Date:  2015-12-04       Impact factor: 12.701

2.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Authors:  Kei Muro; Hyun Cheol Chung; Veena Shankaran; Ravit Geva; Daniel Catenacci; Shilpa Gupta; Joseph Paul Eder; Talia Golan; Dung T Le; Barbara Burtness; Autumn J McRee; Chia-Chi Lin; Kumudu Pathiraja; Jared Lunceford; Kenneth Emancipator; Jonathan Juco; Minori Koshiji; Yung-Jue Bang
Journal:  Lancet Oncol       Date:  2016-05-03       Impact factor: 41.316

3.  Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.

Authors:  Marina Chiara Garassino; Alain Jonathan Gelibter; Francesco Grossi; Rita Chiari; Hector Soto Parra; Stefano Cascinu; Francesco Cognetti; Daniele Turci; Livio Blasi; Carmelo Bengala; Enrico Mini; Editta Baldini; Silvia Quadrini; Giovanni Luca Ceresoli; Paola Antonelli; Enrico Vasile; Carmine Pinto; Gianpiero Fasola; Domenico Galetta; Marianna Macerelli; Diana Giannarelli; Giuseppe Lo Russo; Filippo de Marinis
Journal:  J Thorac Oncol       Date:  2018-05-03       Impact factor: 15.609

4.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

Review 5.  ALK in lung cancer: past, present, and future.

Authors:  Alice T Shaw; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

6.  Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

Authors:  David D W Twa; Fong Chun Chan; Susana Ben-Neriah; Bruce W Woolcock; Anja Mottok; King L Tan; Graham W Slack; Jay Gunawardana; Raymond S Lim; Andrew W McPherson; Robert Kridel; Adele Telenius; David W Scott; Kerry J Savage; Sohrab P Shah; Randy D Gascoyne; Christian Steidl
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

7.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Authors:  Xin Jin; Donglin Ding; Yuqian Yan; Hui Li; Bo Wang; Linlin Ma; Zhenqing Ye; Tao Ma; Qiang Wu; Daniel N Rodrigues; Manish Kohli; Rafael Jimenez; Liguo Wang; David W Goodrich; Johann de Bono; Haidong Dong; Heshui Wu; Runzhi Zhu; Haojie Huang
Journal:  Mol Cell       Date:  2018-12-06       Impact factor: 17.970

9.  Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer.

Authors:  Maher Albitar; Sucha Sudarsanam; Wanlong Ma; Shiping Jiang; Wayne Chen; Vincent Funari; Forrest Blocker; Sally Agersborg
Journal:  Oncotarget       Date:  2018-02-08

Review 10.  The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.

Authors:  Jimin Yuan; Xiaoduo Dong; Jiajun Yap; Jiancheng Hu
Journal:  J Hematol Oncol       Date:  2020-08-17       Impact factor: 17.388

View more
  77 in total

1.  The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.

Authors:  Ping Zhu; Guiyu Kang; Yang Jiao; Chengzhi Gui; Huiping Fan; Xiangying Li; Yanfei Jia; Lulu Zhang; Xiaoli Ma
Journal:  Hum Cell       Date:  2022-05-20       Impact factor: 4.174

Review 2.  Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.

Authors:  Zhaohui Jin; Frank A Sinicrope
Journal:  J Clin Oncol       Date:  2022-06-01       Impact factor: 50.717

3.  Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer.

Authors:  Sung Eun Lee; Gun-Young Jang; Ji Won Lee; Sang Hyeon Park; Hee Dong Han; Yeong-Min Park; Tae Heung Kang
Journal:  Cancer Immunol Immunother       Date:  2022-05-24       Impact factor: 6.630

Review 4.  Next-generation engineered nanogold for multimodal cancer therapy and imaging: a clinical perspectives.

Authors:  Madhusudhan Alle; Garima Sharma; Seung-Hwan Lee; Jin-Chul Kim
Journal:  J Nanobiotechnology       Date:  2022-07-02       Impact factor: 9.429

5.  Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer.

Authors:  Xi Chen; Qianqian Du; Hongjie Guo; Qiaojun He; Bo Yang; Ling Ding
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 6.  Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas.

Authors:  Gayaththri Vimalathas; Bjarne Winther Kristensen
Journal:  Neuropathol Appl Neurobiol       Date:  2021-10-20       Impact factor: 6.250

7.  Vesicle transporter GOLT1B mediates the cell membrane localization of DVL2 and PD-L2 and promotes colorectal cancer metastasis.

Authors:  Tengfei Liu; Binbin Liu; Yiting Liu; Xingzhi Feng; Xuefei Jiang; Jiahui Long; Qianling Gao; Zihuan Yang
Journal:  Cancer Cell Int       Date:  2021-05-31       Impact factor: 5.722

Review 8.  Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.

Authors:  Mengke Niu; Ming Yi; Ning Li; Suxia Luo; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2021-03-02

9.  Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.

Authors:  Kenji Morimoto; Junji Uchino; Takashi Yokoi; Takashi Kijima; Yasuhiro Goto; Akira Nakao; Makoto Hibino; Takayuki Takeda; Hiroyuki Yamaguchi; Chieko Takumi; Masafumi Takeshita; Yusuke Chihara; Takahiro Yamada; Osamu Hiranuma; Yoshie Morimoto; Masahiro Iwasaku; Yoshiko Kaneko; Tadaaki Yamada; Koichi Takayama
Journal:  Oncoimmunology       Date:  2021-07-08       Impact factor: 8.110

Review 10.  Microenvironmental regulation of tumour immunity and response to immunotherapy.

Authors:  Mark M Kockx; Mark McCleland; Hartmut Koeppen
Journal:  J Pathol       Date:  2021-05-19       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.